Anthony James Culverwell Buys 6,146 Shares of Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Director Anthony James Culverwell purchased 6,146 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average price of $4.88 per share, for a total transaction of $29,992.48. Following the acquisition, the director owned 40,364 shares in the company, valued at $196,976.32. This trade represents a 17.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Quoin Pharmaceuticals Trading Up 3.5%

QNRX opened at $6.74 on Thursday. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a 12-month low of $3.25 and a 12-month high of $41.80. The firm has a market capitalization of $13.53 million, a PE ratio of -0.27 and a beta of 1.50. The firm has a 50 day moving average of $4.83 and a two-hundred day moving average of $5.88.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.29). As a group, analysts predict that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Quoin Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in QNRX. SummitTX Capital L.P. increased its holdings in shares of Quoin Pharmaceuticals by 54.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock valued at $662,000 after purchasing an additional 35,505 shares in the last quarter. Ikarian Capital LLC acquired a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at $3,052,000. Millennium Management LLC purchased a new stake in Quoin Pharmaceuticals during the fourth quarter worth $1,080,000. Boothbay Fund Management LLC purchased a new stake in Quoin Pharmaceuticals during the fourth quarter worth $863,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Quoin Pharmaceuticals during the fourth quarter valued at $840,000. Institutional investors and hedge funds own 8.63% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, July 20th. ThinkEquity started coverage on Quoin Pharmaceuticals in a report on Monday, June 15th. They issued a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.